Related Experiment Videos
Primary cutaneous marginal center lymphoma - complete remission induced by interferon alpha2a
U Wollina1, S Hahnfeld, H Kosmehl
1Department of Dermatology, Friedrich-Schiller-University Jena, Germany. uwol@derma.uni-jena.de
Journal of Cancer Research and Clinical Oncology
|June 8, 1999
Summary
This case study shows interferon alpha2a effectively treated a rare form of marginal zone lymphoma (MZL) affecting the skin. The patient achieved complete remission with minimal side effects, highlighting a potential therapeutic option for this B-cell lymphoma.
Area of Science:
- Hematology
- Oncology
- Dermatology
Background:
- Marginal zone lymphoma (MZL) is a specific subtype of B-cell lymphoma.
- Primary cutaneous MZL presents unique diagnostic and therapeutic challenges.
Observation:
- A 53-year-old woman presented with disseminated primary cutaneous MZL and secondary lymph node involvement.
- Tumor cells exhibited a CD20/CD79a/kappa/lambda+/bcl-2 positive phenotype with low Ki-67 proliferation.
- No systemic or bone marrow involvement was detected, classifying the disease as Stage IVa MZL with plasmacytic differentiation.
Findings:
- Treatment with subcutaneous interferon alpha2a (9x10^6 U thrice weekly for 1 year) led to complete resolution of skin lesions.
- No lymph node or extracutaneous recurrence was observed during the treatment period.
- The patient maintained complete remission with only Grade I WHO side effects and a Karnofsky index of 90%.
Implications:
- Prolonged interferon alpha monotherapy demonstrates efficacy in managing primary cutaneous MZL.
- This treatment approach may induce complete remission and control disease progression in MZL patients.
- Interferon alpha represents a viable therapeutic strategy for specific B-cell lymphomas, including cutaneous MZL.